Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England
Authors:
- 1 January 2017
- journal article
- research article
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 39, 11-16
Abstract
Aim: To investigate the association between atomoxetine, a drug used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), and suicidal ideation, within a cohort of 2–18-year-old patients in England.Methods: The study was conducted using the observational cohort technique of Modified prescription event monitoring (M-PEM). Patients prescribed atomoxetine were identified from dispensed prescriptions issued by primary care physicians. A customised postal GP questionnaire was used to capture outcome data for suicidal ideation. A matched pair cohort analysis was performed within patients to compare the risk of suicidal ideation in the period after starting atomoxetine with the risk prior to starting atomoxetine; this was stratified by age and concomitant use of methylphenidate. Additional information on patient characteristics, and events of interest was also collected; individual cases of suicidal ideation were qualitatively assessed for drug relatedness.Results: Of the final cohort (n = 4509); 85.5% male (n = 3857), median age 11 years (IQR: 9,14). Primary prescribing indication for atomoxetine was ADHD (n = 4261, 94.6%). Almost a quarter of the cohort had been co-prescribed methylphenidate. Results of the matched pair cohort analysis indicated that the period after starting atomoxetine was not associated with an increase in the incidence of suicidal ideation compared to the period prior to starting treatment (RR: 0.71; CI: 0.48–1.07; P-value: 0.104). Individual case assessment of suicidal ideation suggested a causal association within a number of cases.Conclusions: This study found no evidence of an increased risk of suicidal ideation during treatment with atomoxetine, compared to the period prior to starting treatment. Amongst age specific subgroups, this risk may change. Nonetheless, individual case assessment suggested a causal relationship in some patients, hence physicians need to be aware of the possibility of developing this event, and furthermore consider how best to detect it in this paediatric population. This study demonstrates the importance of combining quantitative statistical analyses with a qualitative case series assessment.Keywords
This publication has 15 references indexed in Scilit:
- Meta-Analysis of Suicide-Related Behavior or Ideation in Child, Adolescent, and Adult Patients Treated with AtomoxetineJournal of Child and Adolescent Psychopharmacology, 2014
- Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideationExpert Opinion on Drug Safety, 2014
- Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based studyBMJ, 2014
- Safety of Attention-Deficit/Hyperactivity Disorder Medications in Children: An Intensive Pharmacosurveillance Monitoring StudyJournal of Child and Adolescent Psychopharmacology, 2012
- Drug safety assessment in clinical trials: methodological challenges and opportunitiesTrials, 2012
- Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009-2011. An Update for CliniciansJournal of Central Nervous System Disease, 2011
- Mortality Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Drug TreatmentDrug Safety, 2009
- Acute suicidality after commencing atomoxetineJournal of Paediatrics and Child Health, 2008
- Hepatic Events Associated with Atomoxetine Treatment for??Attention-Deficit??Hyperactivity DisorderDrug Safety, 2008
- An 18-Year-Old Woman with New-Onset Suicidal Ideation While Being Treated with AtomoxetineJournal of Psychiatric Practice, 2008